{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:50:27Z","timestamp":1793731827768,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.radonc.2023.109792","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T20:54:42Z","timestamp":1688504082000},"page":"109792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Predictors of pathologic fracture and local recurrence following stereotactic body radiation therapy to 505 non-spine bone metastases"],"prefix":"10.1016","volume":"186","author":[{"given":"Eric K","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Korol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saher","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Cumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darby","family":"Erler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy K","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109792_b0005","doi-asserted-by":"crossref","unstructured":"Kougioumtzopoulou A, Zygogianni A, Liakouli Z, Kypraiou E, Kouloulias V. The role of radiotherapy in bone metastases: A critical review of current literature. European Journal of Cancer Care 2017;26:. https:\/\/doi.org\/10.1111\/ecc.12724.","DOI":"10.1111\/ecc.12724"},{"key":"10.1016\/j.radonc.2023.109792_b0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109792_b0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ctrv.2016.09.013","article-title":"Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials","volume":"50","author":"LeVasseur","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2023.109792_b0020","first-page":"695","article-title":"Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer","volume":"30","author":"Coleman","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.radonc.2023.109792_b0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","article-title":"Update on the systematic review of palliative radiotherapy trials for bone metastases","volume":"24","author":"Chow","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(13)70556-4","article-title":"Single versus multiple fractions of repeat radiation for painful bone metastases: A randomised, controlled, non-inferiority trial","volume":"15","author":"Chow","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0035","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","article-title":"Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases","volume":"97","author":"Harstell","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2023.109792_b0040","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109792_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0050","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109792_b0055","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109792_b0060","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109792_b0065","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0070","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.clon.2020.06.018","article-title":"Stereotactic radiosurgery and stereotactic body radiotherapy in the management of oligometastatic disease","volume":"32","author":"Chen","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2023.109792_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1120\/jacmp.v14i4.4065","article-title":"Lung SBRT: Dosimetric and delivery comparison of rapidarc, tomotherapy, and IMRT","volume":"14","author":"Weyh","year":"2013","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2023.109792_b0085","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/0360-3016(93)90548-A","article-title":"Radiation therapy oncology group: Radiosurgery quality assurance guidelines","volume":"27","author":"Shaw","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109792_b0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.phro.2019.08.002","article-title":"Multi-center evaluation of dose conformity in stereotactic body radiotherapy","volume":"11","author":"Lee","year":"2019","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijrobp.2021.09.004","article-title":"International multi-institutional patterns of contouring practice and clinical target volume recommendations for stereotactic body radiation therapy for non-spine bone metastases","volume":"112","author":"Nguyen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109792_b0100","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","article-title":"Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: A randomized phase 2 trial","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0105","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.prro.2020.10.003","article-title":"Phase 2 clinical trial of stereotactic body radiation therapy for painful nonspine bone metastases","volume":"11","author":"Ito","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0110","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases","volume":"127","author":"Erler","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-015-0340-9","article-title":"Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules","volume":"10","author":"Owen","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ijrobp.2015.07.2288","article-title":"Tumor response after stereotactic body radiation therapy to nonspine bone metastases: An evaluation of response criteria","volume":"93","author":"McDonald","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109792_b0125","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2016.03.022","article-title":"Stereotactic body radiation therapy for spinal metastases in the postoperative setting: A secondary analysis of mature phase 1\u20132 trials","volume":"95","author":"Tao","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109792_b0130","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/j.prro.2015.05.004","article-title":"Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?","volume":"5","author":"Amini","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3109\/0284186X.2011.652741","article-title":"A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases","volume":"51","author":"Jhaveri","year":"2012","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"key":"10.1016\/j.radonc.2023.109792_b0140","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/j.prro.2020.02.011","article-title":"Stereotactic body radiation therapy for nonspine bone metastases: International practice patterns to guide treatment planning","volume":"10","author":"Nguyen","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2021.08.011","article-title":"An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases: SBRT to bone oligometastases","volume":"164","author":"Cao","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5301\/tj.5000441","article-title":"Stereotactic body radiotherapy of bone metastases in oligometastatic disease: Prognostic factors of oncologic outcomes","volume":"102","author":"Ursino","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2023.109792_b0155","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.radonc.2007.10.017","article-title":"A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer","volume":"85","author":"Koto","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1748-717X-5-81","article-title":"Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size","volume":"5","author":"Baba","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009249","article-title":"Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma","volume":"96","author":"Kuo","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.radonc.2023.109792_b0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/neuros\/nyx493","article-title":"Vertebral compression fracture after spine stereotactic body radiation therapy: A review of the pathophysiology and risk factors","volume":"83","author":"Faruqi","year":"2018","journal-title":"Clin Neurosurg"},{"key":"10.1016\/j.radonc.2023.109792_b0180","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/j.ijrobp.2012.04.034","article-title":"Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors","volume":"84","author":"Cunha","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109792_b0185","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1200\/JCO.2008.19.3508","article-title":"Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases","volume":"27","author":"Rose","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0190","doi-asserted-by":"crossref","unstructured":"Versteeg AL, Verlaan J-J, Sahgal A, Mendel E, Quraishi NA, Fourney DR, et al. The Spinal Instability Neoplastic Score: Impact on Oncologic Decision-Making. Spine 2016;41:S231\u20137. https:\/\/doi.org\/10.1097\/BRS.0000000000001822.","DOI":"10.1097\/BRS.0000000000001822"},{"key":"10.1016\/j.radonc.2023.109792_b0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2016.09.029","article-title":"Volume of lytic vertebral body metastatic disease quantified using computed tomography-based image segmentation predicts fracture risk after spine stereotactic body radiation therapy","volume":"97","author":"Thibault","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109792_b0200","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/JTO.0b013e3181ae2962","article-title":"Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer","volume":"4","author":"Voroney","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109792_b0205","first-page":"155","article-title":"Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation","volume":"1","author":"Tom\u00e9","year":"2011","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.radonc.2023.109792_b0210","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.radonc.2009.03.022","article-title":"Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: A dose- and volume-response analysis","volume":"91","author":"Pettersson","year":"2009","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023003304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023003304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:27:55Z","timestamp":1759123675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023003304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"alternative-id":["S0167814023003304"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109792","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of pathologic fracture and local recurrence following stereotactic body radiation therapy to 505 non-spine bone metastases","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109792"}}